Kala Pharmaceuticals Inc. said Thursday it has priced its initial public offering at $15 a share. The company sold 6 million shares to raise $90 million in a deal underwritten by J.P. Morgan, BofA Merrill Lynch and Wells Fargo Securities, with Wedbush PacGrow acting as co-manager. The company is developing treatments for inflammation and pain after eye surgery and for temporary relief of signs and symptoms of dry eye disease, with both currently in late-stage trials. The stock will start trading Thursday on the Nasdaq under the ticker symbol "KALA."
Continue Reading Below
Copyright © 2017 MarketWatch, Inc.